Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The clinical trial NCT03797170, titled "Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma," is focused on developing personalized therapeutic approaches for diffuse large B-cell lymphoma (DLBCL). The trial is related to the role of gut microbiota in tumor immunotherapy, as it aims to understand the relationship between immunotherapy and intestinal microbiota in order to formulate personalized immunotherapy programs for patients based on their characteristics. The study is being conducted at the University of Bologna and involves 50 participants. The trial is active, and the most recent update was in November 2022. The trial is part of the ongoing research to enhance the effectiveness of tumor immunotherapy, possibly by leveraging the gut microbiome.
Primary outcome measures:…